

1 **Title:** Evaluation of the accuracy of a multi-infection screening test based on a multiplex
2 immunoassay targeting imported diseases common in migrant populations

3 **Running title:** Multi-infection screening by Luminex technology

4 **Authors**

5 Ruth Aguilar^{#1}, PhD; Angeline Cruz^{#1}, MSc; Alfons Jiménez^{1,2}, PhD; Alex Almuedo¹, MSc;
6 Carme Roca Saumell^{3,4}, PhD; Marina Gigante Lopez⁵, MD; Oriol Gasch⁶, PhD; Gemma
7 Falcó⁷, MD; Ana Jiménez-Lozano⁸, PhD; Angela Martínez-Perez⁹, PhD; Consol Sanchez-
8 Collado¹⁰, MD; Andrea Tedesco¹¹, MD; Manuel Carlos López¹², PhD; María Jesús Pinazo^{1,13},
9 PhD; Thais Leonel¹⁴, MSc; Zeno Bisoffi¹¹, PhD, Prof; Anna Färnert^{15,16}, PhD, Prof; Carlota
10 Dobaño^{†1,13}, PhD Prof; Ana Requena-Méndez^{†1,13,15,16}, MD, PhD.

11

12 1. Barcelona Institute for Global Health (ISGlobal), Hospital Clínic-Universitat de
13 Barcelona. Carrer Roselló 132, 08036 Barcelona, Spain.

14 2. Biomedical *Research* Networking Center for *Epidemiology and Public Health*
15 (CIBERESP). Avenida Monforte de Lemos 3-5, 28029 Madrid, Spain.

16 3. Centre d'Atenció Primària El Clot, Institut Català de la Salut (ICS). Carrer
17 Concilio de Trento 25, 08018 Barcelona, Spain.

18 4. Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona (UB). Carrer
19 Casanova, 143, 08036 Barcelona, Spain

20 5. Centre d'Atenció Primària Center Numància, Institut Català de la Salut (ICS).
21 Carrer Numància 23, 08029 Barcelona, Spain.

22 6. Infectious Diseases Department, Hospital Universitari Parc Taulí. Institut
23 d'Investigació i Innovació Parc Taulí. Universitat Autònoma de Barcelona. Parc
24 Taulí, 1, 08208 Sabadell-Barcelona, Spain.

25 7. Centre d'Atenció Primària Sant Miquel, Institut Català de la Salut (ICS). Carrer
26 Francesc Macià i Llussà, 154, 08401 Granollers-Barcelona, Spain.

27 8. Centre d'Atenció Primària Adrià 5A Marc Aureli, Institut Català de la Salut (ICS).
28 Carrer Vallmajor, 34, 08021 Barcelona, Spain.

29 9. Centre d'Atenció Primària Casanova. Consorci d'Atenció Primària de Salut de
30 l'Eixample (CAPSBE) Casanova. Carrer Rosselló 161, 08036 Barcelona, Spain.

31 10. Centre d'Atenció Primària Torelló, Institut Català de la Salut (ICS). Avenida
32 Pompeu Fabra, 8, 08570 Torelló-Barcelona, Spain.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 33 11. Department of Infectious Tropical diseases and Microbiology, IRCCS Sacro
34 Cuore Don Calabria Hospital. Via Sempreboni 5, 37024 Negrar di Valpolicella,
35 Italy.
- 36 12. Spanish National Research Council (IPBLN-CSIC). Avenida del Conocimiento
37 17, Parque Tecnológico de Ciencias de la Salud, 18016, Granada, Spain.
- 38 13. Biomedical *Research* Networking Center (CIBER) of Infectious Diseases, Carlos
39 III Health Institute (CIBERINFEC, ISCIII). Carrer Melchor Fernández Almagro,
40 3, 28029 Madrid, Spain.
- 41 14. Liver Unit, Hospital Clínic, University of Barcelona, August Pi i Sunyer
42 Biomedical Research Institute (IDIBAPS), Biomedical *Research* Networking
43 Center of Hepatic and Digestive Diseases (CIBEREHD). Carrer Villarroel, 170,
44 08036 Barcelona, Spain.
- 45 15. Department of Medicine Solna, Karolinska Institutet. Solnavägen 1, 17177 Solna-
46 Stockholm, Sweden.
- 47 16. Department of Infectious Diseases, Karolinska University Hospital. Solnavägen 1,
48 17177 Solna-Stockholm, Sweden.

49

50 #Both authors contributed equally.

51 †Both authors contributed equally.

52

53 Grants that funded the project:

54 This study was supported by two grants from Instituto de Salud Carlos III (ISCIII), through
55 the “Fondo de Investigación para la Salud (FIS)”, PI17/02020 and PI20/00866.

56 ARM receives funding from the Strategic Research Program in Epidemiology at Karolinska
57 Institutet.

58 The research team was supported by CIBER-Consorcio Centro de Investigación Biomédica
59 en Red-(CB 2021).

60 MCL was supported by the Programa Estatal I+D+I, Spanish Ministry of Science and
61 Innovation and FEDER (PID2019-109090RB-I00/AEI/10.13039/501100011033).

62 Authors from IRCCS Sacro Cuore Don Calabria Hospital were supported by the Italian
63 Ministry of Health “Fondi Ricerca corrente-L2P4”.

64 Part of the data from this study were presented in the European Conference of Clinical
65 Microbiology and Infectious Diseases in Copenhagen (April 2023).

66

67

68 **Corresponding author**

69 Ana Requena-Méndez

70 Karolinska Institutet, Department of Medicine Solna.

71 Barcelona Institute for Global Health

72 requena.mendez@ki.se

73 Tel: +46702010789

74

75

76

77

78

79

80

81

82 **Abstract**

83 **Background:** In this study we have evaluated the performance of a novel multiplex
84 serological assay with a panel of 8 antigens able to simultaneously detect IgG to HIV, chronic
85 hepatitis B (HBV) and C (HCV), Chagas disease, strongyloidiasis and schistosomiasis as a
86 screening tool for imported diseases in migrants.

87 **Methods:** Six panels of 40 well-characterized, anonymized serum samples from individuals
88 with the respective confirmed infections (n=240) were used as positive controls to assess the
89 sensitivity of the multiplex assay. One panel of 40 sera from non-infected subjects were used
90 to estimate the seropositivity cutoffs for each infection, and 32 additional non-infected sera
91 were used as negative controls to estimate the sensitivity and specificity for each serology.
92 The multi-infection screening test was validated in a prospective cohort of 48 migrants from
93 endemic areas to assess assay performance.

94 The sensitivity of the Luminex assay was calculated as the proportion of positive test results
95 over all positive samples by the primary reference test. The specificity was calculated using
96 32 negative samples. Uncertainty was quantified with 95% confidence intervals (CI) using
97 receiver operating characteristic analyses.

98 **Results:** The sensitivity /specificity were 100%/100% for HIV (p41 antigen), 97.5%/100%
99 (AUC:0.99,[95%CI: 0.96-1.00]) for HBV (core antigen), 100%/100% (AUC:1.00,[95%CI
100 1.00-1.00]) for HCV (core antigen), 92.5%/90.6%,(AUC:0.96,[95%CI 0.91-1.00]) for
101 strongyloidiasis (31-kDa recombinant antigen (NIE)), 97.5%/100%,(AUC:0.97,[95%CI 0.93-
102 1]) for schistosomiasis (combined serpin *Schistosoma mansoni* and *S.haematobium* antigens)
103 and 92.5%/96.9%,(AUC: 0.96,[95%CI 0.92-1.00]) for Chagas disease ([*T.cruzi* kinetoplastid
104 membrane protein-11 (KMP11)]).

105 In the migrant cohort, antibody response to KMP11 correctly identified 14/14(100%)
106 individuals with Chagas disease, whereas HBV-core antigen and NIE-Strongyloides correctly
107 identified 91.7% and 86.4% individuals with chronic hepatitis B and strongyloidiasis
108 respectively.

109 **Conclusions:** We have developed a new 8-plex Luminex assay that is robust and accurate,
110 and could facilitate the implementation of screening programmes for imported diseases in
111 migrant populations.

112

113 **Key words:** Migrants, Hepatitis C virus, Hepatitis B virus, Strongyloides, Schistosomiasis,
114 Chagas disease, Luminex, IgG, sensitivity, specificity, screening, imported diseases, travel-
115 related illnesses.

116

117 INTRODUCTION

118 Migration is a complex and growing global phenomenon, of critical importance to European,
119 North American and other countries such as Australia and New Zealand (Western countries).
120 Most migrants are disproportionately affected by certain infections such as tuberculosis,
121 human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV),
122 and multiple studies have reported higher prevalence of such infections among them
123 compared with autochthonous populations.^{1,2} In 2020, 44% of new HIV diagnoses were
124 attributed to migrants living in the European Union, particularly migrants from sub-Saharan
125 Africa.³ Similarly, migrants from certain regions are at increased risk of hepatitis B and C
126 whereas for other regions, the risk is even lower compared to the autochthonous population.²

127 Other parasitic infections, such as Chagas disease, strongyloidiasis and schistosomiasis,
128 which are not endemic in Western countries, -with the exception of strongyloidiasis in few
129 areas-, are highly prevalent among migrants⁴⁻⁶. Chagas disease, caused by *Trypanosoma cruzi*
130 is a public health concern due to the high pooled prevalence (4.2%) among migrants from
131 Latin-American endemic countries living in Europe⁵, which is particularly high in Bolivian
132 migrants (18%)⁷; but also due to the possibility of autochthonous transmission (congenitally,
133 by transfusion, or transplantation,⁸) with a subsequent increase of related morbidity in
134 national health systems from Western countries, particularly in immunosuppressed patients
135 due to the risk of reactivation.⁹ Strongyloidiasis is also an emerging infection which is of
136 public health concern due to the possibility of being a life-threatening pathology when
137 immunosuppression is established.¹⁰ Schistosomiasis is a neglected tropical disease becoming
138 relevant in low- and non-endemic countries because of the increased migration flows from
139 high-endemic countries. It represents a management challenge due to the lack of clinical
140 awareness and knowledge among health professionals.¹¹

141 Early detection and treatment of these infections can lower the related morbidity and
142 mortality.¹¹ The European Centre for Disease Prevention and Control (ECDC) guidance on
143 screening of infections in migrants,¹² recommends the screening of HIV, HBV, HCV,
144 strongyloidiasis and schistosomiasis. Chagas disease was not included in the ECDC screening
145 and vaccination recommendations document, yet this disease has an impact in Europe's
146 health system and some studies have demonstrated the cost-effectiveness of the strategy of
147 screening migrants from endemic countries at primary care.⁸

148 The feasibility of innovative integrated screening programmes of infectious diseases, has
149 been proven in different settings including primary care units in United Kingdom, United
150 States, Canada and Spain.^{11,13–15}

151 Antibody-based assays are used for assessing the exposure to different infections among
152 migrants including HIV or viral hepatitis,¹⁶ and also parasites (*Strongyloides stercoralis*¹⁷,
153 *Schistosoma* spp¹⁸ and *T. cruzi*¹⁹) for which methods aiming at the direct detection of the
154 parasites or their DNA have lower sensitivity. Quantitative suspension array assays
155 simultaneously detecting antibodies to multiple pathogens using a single specimen can
156 support a more cost-effective implementation of integrated disease surveillance systems. In
157 addition, rapid tests with single but also with multiple biomarkers are gaining popularity in
158 low-income countries. In this regard, the dual rapid HIV and *Treponema pallidum* diagnostic
159 test is an example of multiple-test that has been utilized in integrated screening systems.

160 Luminex technology is gaining traction in diagnosis because of the ease, high throughput,
161 and minimal sample volume requirements. It has been used to perform the surveillance of
162 tropical viral infections,²⁰ enteropathogens,²¹ or malaria.²² More recently another new
163 multiplex-test has been developed to detect HIV, viral hepatitis, herpes and *T. pallidum*.²³

164 Our study aimed to develop a new multiplex serological assay using 10 antigens to quantify
165 IgG to six pathogens that are prevalent in migrant populations living in Catalonia (Spain),
166 including HIV, HBV, HCV, *T. cruzi*, *S. stercoralis* and *Schistosoma* spp., and to estimate its
167 sensitivity and specificity compared with primary reference standard tests for each infection.

168

169 **METHODS**

170 **Study design**

171 The study was performed using six panels of archived, fully anonymized well-characterized
172 coded serum samples previously diagnosed for the different infections, plus a group of
173 samples from non-infected subjects.

174 Each panel consisted of 40 positive control specimens for each pathogen (HIV, HBV, HCV,
175 *T. cruzi*, *Strongyloides* and *Schistosoma*). HIV positive controls were determined with the
176 Determine HIV-1/2 Rapid Test (Abbott Laboratories) and confirmed with the Unigold rapid
177 test (Trinity Biotech). HBV and HCV positive controls were determined by RNA quantitative
178 testing that measures the viral load. The schistosomiasis positive controls were positive for

179 stool and/or urine test depending on the species. The strongyloidiasis positive controls were
180 individuals diagnosed with strongyloidiasis and included in a clinical trial that assessed the
181 effectiveness of ivermectin²⁴ and for which the inclusion criteria were having a positive
182 faecal test for *S. stercoralis* or having a positive serological test at high titers irrespective of
183 the result of faecal test. High titers were assessed as at least 160 titer for the indirect
184 fluorescent antibody test (IFAT)- that is, whole serum dilution 1/160, and at least 2x
185 normalized optical density(OD) for the IVD Research ELISA, -that is, the ratio between OD
186 of the sample and that of the weak positive control-²⁵. The accuracy of these tests at these
187 high titers have been validated showing that they approach 100% specificity, while
188 maintaining 70% sensitivity.²⁵ The *T. cruzi* positive controls were obtained from a serum
189 biobank of Chagas cases defined by being positive in at least two serological tests using
190 different recombinant antigens. For the parasitic infections, further details of the serological
191 titers, and faecal or urine samples in case of strongyloidiasis and schistosomiasis are reported
192 in Annex 1. From the panel of 72 sera of healthy subjects, 40 samples were used to estimate
193 the seropositivity cutoffs for the different serologies, and 32 were used as negative controls to
194 estimate the specificity for each serology. We validated the multi-infection screening test in a
195 prospective cohort of 48 migrants with epidemiological exposure risk to the above infections
196 depending on the country of origin. They were recruited during the implementation of a
197 multi-disease screening program for asymptomatic migrants attended at primary care units in
198 Catalonia, (January 2019 - December 2020). They were tested for each infection with the
199 reference method depending on the exposure risk.

200 The reference serological tests used to assess the accuracy of the Luminex in the prospective
201 migrant cohort were performed according to each centre's referral laboratory for HIV and
202 viral hepatitis; for *Strongyloides*, an enzyme-linked immuno-sorbent assay (ELISA) based on
203 IVD-*S.stercoralis* crude antigen (SCIMEDX, Dover-NJ,) or an in-house
204 immunofluorescence; for *Schistosoma*, an ELISA or an in-house indirect-haemagglutination
205 test (Schistosomiasis-Fumouze, Levallois-Perret,); for *T. cruzi*, a commercial ELISA with
206 recombinant antigens (BioELISA-Chagas, Biokit-SA), and an in-house ELISA with whole
207 epimastigotes antigen²⁶, with diagnosis defined by positivity in both serological tests.

208 **Multi-infection IgG Luminex assay.**

209 The 10 antigens initially selected for the study are listed in Table 1. P24 (core antigen) and
210 gp41 (envelope antigen) were selected for HIV serology, the first one for being indicative of
211 acute infection²⁷ and the second one for being highly immunogenic during seroconversion²⁸

212 the 31-kDa recombinant antigen (NIE) antigen was selected for the serology of *S.*
213 *stercoralis*, as ELISAs based on this antigen have shown high sensitivity in the range of 71–
214 84%^{25,29,30} *S.mansoni* (Sm) and *S.haematobium* (Sh) serpins were selected for the serology of
215 the corresponding species for being reported as promising species-specific diagnostic
216 antigens by Luminex³¹, hepatitis C core and nonstructural protein 3 (NS3) antigens were
217 tested for chronic hepatitis C infection, the core antigen is currently used for diagnostic³² and
218 the NS3 antigen has also been reported as seroreactive³³, hepatitis B core (anti-HBc) antigen
219 was used for the detection of chronic hepatitis B infection as the presence of IgG indicates
220 ongoing infection, and people who have immunity to hepatitis B from a vaccine do not
221 develop anti-HBc³⁴. Finally, paraflagellar rod proteins 2 (PFR2)1 and *T.cruzi* kinetoplastid
222 membrane protein-11 (KMP11) antigens were selected for being previously reported as good
223 markers of *T.cruzi* infection³⁵.

224 Each of the 10 antigens included in the Luminex panel was coupled to a specific magnetic
225 microsphere region; the optimal bead-coupling concentration was determined for each using
226 the same methodology, as described previously.³⁶

227 A detailed description of the assays is provided in Annex 2. Briefly, 361 samples were tested
228 together with serial dilutions of a positive control to generate a standard curve for assay
229 quality control, plus 3 technical blanks. Antigen-coupled microspheres were added in
230 multiplex to the 384-well plate (2000 beads/ antigen/ well) and mixed with test samples,
231 positive controls, and blanks. Final dilution of test samples was 1/250. The plate was
232 incubated for 1 h at room temperature in agitation and protected from light. Then, the plate
233 was washed and 25µL of goat anti-human IgG-phycoerythrin,(1:400) were added to each well
234 and incubated for 30 min. The plate was washed again and microspheres resuspended with
235 Luminex Buffer, to be acquired on the Flexmap-3D® reader. At least 50
236 microspheres/analyte/well were acquired, and median fluorescence intensity (MFI) was
237 reported. Annex 3 shows the standard curves made of 20 serial dilutions of the positive
238 control. Reference standard results were blinded to the researchers who performed the
239 Luminex test.

240 **Data analysis**

241 MFI cutoffs for seropositivity were calculated for each antigen as the exponential function of
242 the mean plus 2 standard deviations (SD) or 3SD of log₁₀-transformed MFIs of 40 negative
243 controls randomly selected among the specimens from 72 subjects with no previous exposure

244 to any infection. The other 32 negative controls were used to estimate the specificity of the
245 Luminex assay vs the reference tests. Thereafter, for each infection, the evaluation of the
246 Luminex assay performance used 72 specimens with known serological status (40 positive
247 and 32 negative samples). The sensitivity of the Luminex test was calculated as the
248 proportion of positive results (based on the cut-off with 2SD) over all positive samples by the
249 primary reference test. Sensitivity was also calculated with the cutoff with 3SD. Similarly,
250 specificity was calculated over 32 control negative samples from the group of healthy
251 controls using both 2SD and 3SD cutoffs. Uncertainty was quantified with 95% confidence
252 intervals (CI) using receiver operating characteristic (ROC) analyses. Finally, the sensitivity
253 and specificity were also estimated in a panel of samples prospectively collected from 48
254 migrants at risk of infections.

255 **Ethics**

256 Positive and negative control samples used to develop the assay were obtained from
257 collections registered at the Instituto de Salud Carlos III, Hospital Clínic(Barcelona)/ISGlobal
258 biobanks and Sacro-Cuore Hospital Tropica-Biobank (Annex 4). The study protocol and
259 informed consent from migrants whose samples were prospectively collected were approved
260 by the ethical committee at Hospital Clínic, (HCB/2017/0847). Results are reported
261 according to the STARD-checklist (Annex 5).

262

263 **RESULTS**

264 **Accuracy of the multi-infection Luminex assay on a reference panel of human samples**

265 We evaluated the performance of the novel multiplex serological assay on a panel of human
266 sera with known infection status. First, we estimated the seropositivity cutoffs for each of the
267 antigens in the Luminex panel using 2 and 3SD, summarized in Annex 6.

268 Figure 1 represents the IgG serological levels (\log_{10} MFI) against each antigen in the Luminex
269 panel in 32 negative and 246 positive control samples (1A), and 48 test samples from
270 migrants exposed to the infections (1B).

271 Using a 2SD cutoff, the sensitivity was generally high (>90%) for the majority of the
272 antigens, whereas the specificity depended on the pathogen and antigen (Table 2 and Figure
273 2). The sensitivity and specificity of the Luminex test for detecting HIV using the gp41
274 recombinant protein determined by ROC analysis were 100% using both 2SD and 3SD

275 cutoffs. In contrast, the p24 protein performed worse, with a sensitivity of 87.5% and a
276 specificity of 96.9% with the 2SD cutoff, and 80% sensitivity at 3SD cutoff (Figure 2A).

277 The HBV core antigen showed a sensitivity of 97.5% at 2SD-cutoff and 95% at 3SD-cutoff,
278 and a specificity of 100% (2SD and 3SD-cutoff), (AUC: 0.99, [95%CI: 0.96-1.00]), (Figure
279 2B). The HCV core antigen showed a 100% sensitivity at 2SD-cutoff (97.5% at 3SD-cutoff)
280 and a specificity of 100% (2SD and 3SD-cutoff),(AUC: 1.00,[95%CI 1.00-1.00]), (Figure
281 2C).

282 *Strongyloides*-NIE antigen reported a sensitivity of 92.5% (2SD and 3SD-cutoff) and
283 specificities of 90.6% (2SD-cutoff) and 100% (3SD-cutoffs), (AUC:0.96, [95%CI 0.91-
284 1.00]), (Figure 2D). In a restricted analysis (Annex 7) to those samples that tested positive in
285 feces [(either by polymerase chain reaction (PCR) test or any other direct technique)], the
286 performance of the NIE antigen in Luminex with the 3SD cutoff improved to 100%
287 sensitivity (AUC: 1.00, [95%CI 1.00-1.00]).

288 The sensitivity and specificity of the Luminex test to detect schistosomiasis was 97.5% and
289 93.8% (2SD cutoff),(AUC:0.97, [95%CI 0.93-1.00]) using *S. haematobium* (Sh) and *S.*
290 *mansoni* (Sm) serpin antigens together, (Figure 2E). Interestingly, the sensitivity of the
291 serpin-Sh antigen was 100% for detecting *S. haematobium* infections whereas the sensitivity
292 of the serpin-Sm antigen was 96% for detecting *S. mansoni* infections (Annex 7).

293 The *T. cruzi* KMP11 antigen performed better (Sen 92.5%, Spec 96.9%, AUC:0.96, [95%CI
294 0.92-1.00]) compared to the PFR2 antigen (Sen 77.5%; Spec 93.8, AUC:0.87, [95%CI 0.80-
295 0.94]). Furthermore, when combining both antigens, the sensitivity increased to 95%
296 (AUC:0.97, [95%CI 0.93-1.00]) (Figure 2F). There were two samples in the *T. cruzi* infection
297 panel that resulted indeterminate by the reference test, and it was necessary a third serological
298 test to confirm the infection. After excluding these samples from the analysis (Annex 7), the
299 sensitivity increased to 97.4% at 2SD cutoff (AUC:0.98, [95%CI 0.95-1.00]).

300 In order to assess possible cross-reactivities, we evaluated for each infection the false positive
301 rate among the individuals from the six panels of positive controls (Annex 8). Overall, the
302 Luminex serology showed a low frequency of false positives, except for *S. stercoralis*
303 showing a rate of 66% (12/18) and 50% (9/18) among *Schistosoma* spp. Infections at a cutoff
304 of 2SD and 3SD respectively, and 62% (13/21) and 38% (8/21) in *Schistosoma* spp. and HBV
305 coinfections at a cutoff of 2SD and 3SD respectively. There were 25% (5/20) false positives

306 for HIV and 36% (4/11) for HCV in *Schistosoma* spp. and HBV coinfections at a cutoff of
307 2SD that were not observed at 3SD.

308 **Accuracy of the multi-infection Luminex assay on migrant's cohort**

309 There were no positive reference tests for HIV, HCV, and schistosomiasis among the
310 migrant's cohort, therefore the sensitivity and AUC of the Luminex test for these infections
311 could not be evaluated. The specificities assessed for each of these infections are detailed in
312 table 3.

313 Among the 48 individuals tested for HBV, 11 of them had a positive anti-HBc test result. The
314 core HBV antigen tested in Luminex showed a sensitivity of 100% and specificity of 89.2%
315 (2SD-cutoff). For the KMP11- Chagas antigen, the Luminex assay correctly identified (2SD
316 and 3SD-cutoffs) the 14 positive and 16 negative cases detected with the reference method
317 (100% Sens and 100% Spec, AUC: 1.00, [95%CI 1.00-1.00]). The NIE-antigen showed
318 83.3% sensitivity and 86.8% specificity, at 2SD-cutoff.

319 We also assessed for cross-reactivities among the 48 individuals from the migrant's cohort
320 (Annex 9), and frequency of false positives was overall low, except for *S. stercoralis*
321 infections with 20% (2/10) false positives among *T. cruzi* but only at 2SD and 28% (2/7)
322 among HBV infections at 2SD and 15% (1/7) at 3SD cutoff. HIV showed 32% (4/12) false
323 positives among the *T. cruzi* infected individuals at 2SD (only 1 at 3 SD), and *Schistosoma*
324 spp. showed 28% (2/7) among HBV infected individuals, using the 2SD and 2 SD cutoff.

325

326 **DISCUSSION**

327 We have developed a 8-plex Luminex assay for the simultaneous detection of IgG against
328 HIV, HBV, HCV, *Schistosoma* spp, *S. stercoralis* and *T. cruzi*. To our knowledge, this is the
329 first multiplex test that simultaneously detects several viral and parasitic infections based on
330 serological tests that are prevalent in migrant populations. Although 10 antigens were initially
331 evaluated, only 8 of them showed a good performance.

332 Our 8-plex assay results showed a good agreement with the reference tests, being highly
333 accurate to detect most pathogens, particularly gp41-HIV and HCV-core antigen, (100%
334 sensitivity), the combination of *Schistosoma* serpin antigens (97.5%), HBV core antigen
335 (97.5%) and the combination of *T. cruzi* antigens (95%).

336 For the infections for which two antigens were tested, the sensitivity of the test increased for
337 Chagas disease and schistosomiasis, whereas for HIV the combination of p24 and gp41
338 antigens slightly decreased the specificity of the test compared with the use of the gp41
339 antigen alone. P24 antigen tends to negativize over time after the infection³⁷, as it is only
340 detected in blood during early stages of the primoinfection, thus it is not reliable for screening
341 except for the detection of recent infections.³⁸ Similarly to other studies,³⁹ for HCV the
342 combination of NS3 with the core antigen decreased the specificity of the test compared with
343 the core antigen alone. The performance of HIV and HBV antigens was similar compared
344 with a previous Luminex study, whereas the core HCV antigen has demonstrated better
345 performance.²³ However HIV gp41 and HCV-core antigens showed some false positives in
346 *Schistosoma* spp. and HBV coinfections, and HIV also in *T.cruzi* infections, suggesting some
347 room for improvement.

348 As previously described, the performance of the recombinant *Strongyloides*-NIE antigen
349 (sensitivity 92.5%) is not as good as other commercially available tests based on crude
350 antigens.²⁵ However, the sensitivity was 100% for those infections detected by microscopy or
351 PCR. Therefore, the lower sensitivity of NIE by Luminex can be attributed to a poorer
352 diagnostic capability of the recombinant antigen compared with crude antigens.⁷ However,
353 the *Strongyloides* serology with crude antigen may give false positives due to cross-reactivity
354 with other helminths, such as, filarial infections, *Ascaris lumbricoides* infection, and acute
355 schistosome infections⁴⁰, thus these specimens could also be true negatives wrongly
356 characterized by the reference test. In fact, when assessing the rate of false positives due to
357 possible cross reactivities, *S. stercoralis* showed a high prevalence of false positives among
358 other infections suggesting the need to improve the specificity for the NIE antigen.

359 Concerning Chagas disease, although the combination of both antigens showed a better
360 sensitivity, the KMP11 antigen performed much better compared with PFR2 antigen to detect
361 *T. cruzi*, improving even the accuracy when excluding borderline results detected by the
362 reference test, which suggests that this antigen is performing similar compared with other
363 serological tests developed for *T. cruzi* screening.⁴¹ In any case, the diagnosis of Chagas
364 disease by Luminex should be confirmed with another serological test using a different
365 recombinant protein, as standard procedure.

366 Interestingly, when the Luminex assay was tested in a prospective sample of migrant
367 individuals coming from countries endemic for the infections tested, the assay showed a good
368 accuracy to detect most infections, although sensitivity was lower for strongyloidiasis,

369 suggesting that this Luminex panel may be promising as a screening tool. However, the
370 migrants sample size was very small and there were no patients with patients with
371 schistosomiasis, HIV, and hepatitis C.

372 We have tested the performance of the 10 antigens using two different cutoffs. The 2SD-
373 cutoff gives higher sensitivities by losing some specificity, while the 3SD-cutoff gives lower
374 sensitivities but 100% specificity for all infections. In the context of screening of migrant
375 populations, higher sensitivities are more important than 100% specificities, as having
376 infected undiagnosed individuals is not desirable, therefore false negative cases should be
377 minimized.

378 Overall, the use of bead-based multiplex assays is gaining recognition in diagnosis of
379 infections because of the ease, high throughput, and minimal sample/reagent volume
380 requirements⁴²⁻⁴⁴ allowing measuring up to 100 analytes/per sample, and the FlexMap-3D
381 platform (the one used in this study) up to 500 analytes per sample, with comprehensive
382 reductions in time and cost. Remarkably, multiplexing more than one antigen may increase
383 the sensitivity of pathogen detection compared to single-biomarkers. In addition, Luminex
384 panels are flexible and can be adapted to the epidemiological risk of individuals (i.e., the
385 country of origin). Thus, for example *T cruzi* antigen could be only included in a specific
386 Luminex panel for Latin American migrants.

387 In this specific study, we evaluated the diagnostic utility of a multiplex test focusing on the
388 positivity or negativity of samples, however antibody levels could be useful in studies
389 addressing IgG kinetics since time of infection, or IgG levels depending on viral or parasitic
390 loads.

391 Although the Luminex technology itself is not novel, to our knowledge, this is the first
392 multiplex test that simultaneously detects several viral and parasitic infections that are
393 prevalent in migrant populations based on serological tests. The simultaneous classification
394 for the presence or absence of multiple pathogens in a single assay has the potential to
395 revolutionize and simplify the public health and diseases surveillance in endemic areas where
396 the infections are prevalent,⁴⁴ and also the implementation of screening programmes in
397 migrant populations. Moreover, 5 of the 10 proteins used in the panel are not commercially
398 available thus have been produced in house, and for some of them this is the first time that
399 their diagnostic performance is reported as part of a multi-diagnostic infection test.

400 In addition, the 8-plex assay overcomes many of the laboratory infrastructure requirements of
401 the single infection diagnostic testing, thereby simplifying the logistics. This makes it a more
402 accessible test for settings that may not have either the technical knowledge or the

403 infrastructure capacity to conduct the single diagnostic tests using a dedicated platform for
404 each of them (i.e., primary care). In this regard, the current existence of benchtop compact
405 easy-to-use multiplex equipment, would facilitate the development of a point of care version
406 of the assay in primary care.

407 While further work is needed to optimize and validate this 8-plex assay, and maybe expand it
408 to other infections, and to other assays using non-invasive samples such as mucosa or saliva,
409 it has the potential to drastically reduce the disease burden in settings where testing has often
410 been limited, particularly for imported parasitic diseases.

411 A detailed comparative cost-analysis between the multiplex assay and the individual standard
412 conventional tests for each infection is in progress, this test has substantial potential to
413 improve diagnostic testing, based on this proof-of-concept study.

414 The main limitation of the study is the small sample size of the prospective sample with no
415 diagnosed cases for some of the infections. For this reason, we plan to conduct a more robust
416 prospective study for the validation of the 8-plex assay. Another limitation of the study is the
417 lack of a proper challenge panel made up of samples from infections and conditions that may
418 cause potential cross-reactivity (i.e., filariasis in the case of strongyloidiasis)⁷. The reason
419 was the lack of samples with known unique infections for this purpose. Instead, we have used
420 the data from the individuals from the six panels of positive controls and the 48 tested
421 individuals with information on other infections as challenge panels. We are measuring IgG,
422 which is indicative of exposure, not distinguishing between current or past infection.

423 However, the Luminex platform allows measuring any isotype or IgG subclass, thus IgM or
424 IgA could be used in combination with IgG to distinguish recent from past infections. In
425 addition, the use of specific antigens can be helpful to determine the approximate time of
426 infection.

427

428 **Conclusions**

429 We present a proof-of-principle of the excellent performance of a high through put single test
430 using multiplexed antigens with a minimal sample volume that can detect multiple infections,
431 common in migrant populations. Our 8-plex assay has shown to be robust and accurate,
432 although further prospective study should validate the reproducibility of the assay. This test
433 could facilitate the implementation of screening programmes particularly in non-hospital-
434 based settings where the detection of single pathogens can be logistically challenging and
435 expensive.

436

437 **Acknowledgements**

438 We are grateful to all patients who participated in this study, the general practitioners, nurses,
439 and other staff from the primary care centres and hospitals who were committed to perform
440 the field work required for the study while maintaining their daily tasks. Specially, we
441 acknowledge the work carried by Maria Luisa Machado and Silvia Capilla from Hospital
442 Universitari Parc Taulí. Special thanks to the research group at the IRCCS Sacro Cuore Don
443 Calabria Hospital for providing the positive control samples for strongyloidiasis (part of
444 them) and schistosomiasis, in particular to Stefano Tais and Monica Degani, to Jose Munoz
445 (Hospital Clinic, Barcelona) for facilitating positive control samples for strongyloidiasis (part
446 of them) and Denise Nanche (ISGlobal) for information on the HIV positive control samples.
447 We are also grateful to M^a Carmen Thomas from the Institute of Parasitology
448 and Biomedicine López Neyra for supplying the Chagas disease antigens, Thomas
449 Nutman (NIH/NIAID,USA), Sukwan Handali (CDC) for supplying the NIE, Satoshi
450 Kaneko (Nagasaki University, Japan) for donating the Sm and Sh serpins, and Marta
451 Vidal, Rebeca Santano and Inocencia Cuamba for support in the antigen procurement and
452 characterization.

453 **Funding**

454 This study was supported by two grants from Instituto de Salud Carlos III (ISCIII), co-
455 financed by the European Regional Development Fund (FEDER) from the European Union,
456 through the “Fondo de Investigación para la Salud (FIS)”, PI17/02020 and PI20/00866. ARM
457 receives funding from the Strategic Research Program in Epidemiology at Karolinska
458 Institutet. This research team was supported by CIBER-Consortio Centro de Investigación
459 Biomédica en Red-(CB 2021), Instituto de Salud Carlos III, Ministerio de Ciencia e
460 Innovación and Unión Europea. MCL was supported by the Programa Estatal I+D+I, Spanish
461 Ministry of Science and Innovation and FEDER (PID2019-109090RB-
462 I00/AEI/10.13039/501100011033). Authors from IRCCS Sacro Cuore Don Calabria Hospital
463 were supported by the Italian Ministry of Health “Fondi Ricerca corrente-L2P4”. ISGlobal
464 receives support from the Spanish Ministry of Science and Innovation through the “Centro de
465 Excelencia Severo Ochoa 2019-2023” Program (CEX2018-000806-S), and support from the
466 Generalitat de Catalunya through the CERCA Program.

467 The funders of the study had no role in the study design, data collection, data analysis, data
468 interpretation or writing of the manuscript.

469 **Author contribution**

470 Study design by ARM, RA, AJ and CD. Field work done by CRS, MGL, OGB, GF, AJL,
471 AMP, RSC. Sample processing carried out by AJ, RA and CD. Methodology developed by
472 RA, AC and ARM. Interpretation of results executed by AC, ARM and AJ. The manuscript
473 has been drafted by RA, AC, AJ, CD and ARM. All authors have contributed to the writing,
474 reviewing and editing of the publication.

475

476 **REFERENCES**

- 477 1 European Centre for Disease Prevention and Control. Assessing the burden of key
478 infectious diseases affecting migrant populations in the EU/EEA. Stockholm, 2014
479 DOI:10.2900/28792.
- 480 2 Lazarus J V., Bromberg DJ, del Amo J, et al. Hepatitis C prevalence among the
481 migrant population in Spain: A systematic review and meta-analysis. *Enferm Infecc*
482 *Microbiol Clin* 2019; 37: 222–30.
- 483 3 European Centre for Disease Prevention and Control, WHO Regional Office for
484 Europe. HIV/AIDS surveillance in Europe 2021 - 2020 data. Stockholm: ECDC, 2021.
- 485 4 Asundi A, Beliavsky A, Liu XJ, et al. Prevalence of strongyloidiasis and
486 schistosomiasis among migrants: a systematic review and meta-analysis. *Lancet Glob Health*
487 2019; 7: e236–48.
- 488 5 Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in
489 Latin-American migrants living in Europe: a systematic review and meta-analysis. *PLoS*
490 *Negl Trop Dis* 2015; 9: e0003540.
- 491 6 Navarro M, Reguero L, Subir C, Bl A, Requena-m A. Estimating chagas disease
492 prevalence and number of underdiagnosed , and undertreated individuals in Spain. 2022 May-
493 June; 47:102284. DOI:10.1016/j.tmaid.2022.102284.
- 494 7 1 European Centre for Disease Prevention and Control. Assessing the burden of
495 key infectious diseases affecting migrant populations in the EU/EEA. Stockholm, 2014
496 DOI:10.2900/28792.
- 497 2 Lazarus J V., Bromberg DJ, del Amo J, et al. Hepatitis C prevalence among the
498 migrant population inSpain: A systematic review and meta-analysis. *Enferm Infecc Microbiol*
499 *Clin* 2019; 37: 222–30.
- 500 3 European Centre for Disease Prevention and Control, WHO Regional Office for
501 Europe. HIV/AIDS surveillance in Europe 2021 - 2020 data. Stockholm: ECDC, 2021.
- 502 4 Asundi A, Beliavsky A, Liu XJ, et al. Prevalence of strongyloidiasis and
503 schistosomiasis among migrants: a systematic review and meta-analysis. *Lancet Glob Health*
504 2019; 7: e236–48.
- 505 5 Requena-Méndez A, Aldasoro E, de Lazzari E, et al. Prevalence of Chagas disease in
506 Latin-American migrants living in Europe: a systematic review and meta-analysis. *PLoS*
507 *Negl Trop Dis* 2015; 9: e0003540.
- 508 6 Navarro M, Reguero L, Subir C, Bl A, Requena-m A. Estimating chagas disease
509 prevalence and number of underdiagnosed , and undertreated individuals in Spain. 2022; 47.
510 DOI:10.1016/j.tmaid.2022.102284.
- 511 7 Requena-Mendez A, Buonfrate D, Bisoffi Z, Gutiérrez JM. Advances in the
512 Diagnosis of Human Strongyloidiasis. *Curr Trop Med Rep* 2014; 1: 207–15.

- 513 8 Requena-Méndez A, Bussion S, Aldasoro E, et al. Cost-effectiveness of Chagas
514 disease screening in Latin American migrants at primary health-care centres in Europe: a
515 Markov model analysis. *Lancet Glob Health* 2017; 5: e439–47.
- 516 9 Requena-Méndez A, Albajar-Viñas P, Angheben A, Chiodini P, Gascón J, Muñoz J.
517 Health Policies to Control Chagas Disease Transmission in European Countries. *PLoS Negl*
518 *Trop Dis* 2014 Oct 30; 8(10):e3245. DOI:10.1371/journal.pntd.0003245.
- 519 10 Buonfrate D, Requena-Mendez A, Angheben A, et al. Severe strongyloidiasis: a
520 systematic review of case reports. *BMC Infect Dis* 2013 Feb 8; 13: 78.
- 521 11 Sequeira-Aymar E, Cruz A, Serra-Burriel M, et al. Improving the detection of
522 infectious diseases in at-risk migrants with an innovative integrated multi-infection screening
523 digital decision support tool (IS-MiHealth) in primary care: A pilot cluster-randomized
524 controlled trial. *J Travel Med* 2022 Nov 4; 29(7):taab100.
- 525 12 ECDC. Public health guidance on screening and vaccination for infectious diseases in
526 newly arrived migrants within the EU/EEA. 2018.
- 527 13 Eborall H, Wobi F, Ellis K, et al. Integrated screening of migrants for multiple
528 infectious diseases : Qualitative study of a city-wide programme. *EClinicalMedicine* 2020
529 Apr 18; 21:100315.
- 530 14 María JM, Vivancos J, Lidia CG, et al. Hepatitis C and HIV combined screening in
531 primary care : A cluster randomized trial. *J Viral Hepat.* 2021 Feb;28(2):345-352.
- 532 15 Redditt VJ, Graziano D. Health status of newly arrived refugees in Toronto , Ont. *Can*
533 *Fam Physician.* 2015 Jul; 61(7): e303–e309
- 534 16 Zangiabadian M, Zamani A, Nasiri MJ, Behzadi E, Fooladi AAI. Diagnostic
535 Accuracy and Validity of Serological and Molecular Tests for Hepatitis B and C. *Curr Pharm*
536 *Biotechnol* 2022; 23: 803–17.
- 537 17 Requena-Mendez A, Chiodini P, Bisoffi Z, et al. The laboratory diagnosis and follow
538 up of strongyloidiasis: a systematic review. *PLoS Negl Trop Dis* 2013; 7: e2002.
- 539 18 Agbata EN, Morton RL, Bisoffi Z, et al. Effectiveness of Screening and Treatment
540 Approaches for Schistosomiasis and Strongyloidiasis in Newly-Arrived Migrants from
541 Endemic Countries in the EU/EEA: A Systematic Review. *Int J Environ Res Public Health.*
542 2018 Dec 20;16(1):11. DOI:10.3390/ijerph16010011.
- 543 19 Abras A, Gállego M, Llovet T, et al. Serological Diagnosis of Chronic Chagas
544 Disease: Is It Time for a Change? *J Clin Microbiol* 2016; 54: 1566–72.
- 545 20 Raulino R, Thaurignac G, Butel C, et al. Multiplex detection of antibodies to
546 Chikungunya, O'nyong-nyong, Zika, Dengue, West Nile and Usutu viruses in diverse non-
547 human primate species from Cameroon and the Democratic Republic of Congo. *PLoS Negl*
548 *Trop Dis* 2021; 15: 1–20.
- 549 21 Williams C, Cumming O, Grignard L, et al. Prevalence and diversity of enteric
550 pathogens among cholera treatment centre patients with acute diarrhea in Uvira, Democratic
551 Republic of Congo. *BMC Infect Dis* 2020 Oct;20(1):741. DOI:10.1186/S12879-020-05454-0.

- 552 22 Tetteh KKA, Wu L, Hall T, et al. Optimisation and standardisation of a multiplex
553 immunoassay of diverse *Plasmodium falciparum* antigens to assess changes in malaria
554 transmission using sero-epidemiology. *Wellcome Open Res* 2020 Apr 23;4:26.
555 DOI:10.12688/WELLCOMEOPENRES.14950.2.
- 556 23 Yufenyuy EL, Vedapuri S, Zheng A, et al. Development of a Bead-Based Multiplex
557 Assay for Use in Multianalyte Screening and Surveillance of HIV, Viral Hepatitis, Syphilis,
558 and Herpes. *J Clin Microbiol* 2022 May 18;60(5):e0234821. DOI:10.1128/JCM.02348-21.
- 559 24 Buonfrate D, Salas-Coronas J, Muñoz J, et al. Multiple-dose versus single-dose
560 ivermectin for *Strongyloides stercoralis* infection (Strong Treat 1 to 4): a multicentre, open-
561 label, phase 3, randomised controlled superiority trial. *Lancet Infect Dis* 2019; 19: 1181–90.
- 562 25 Bisoffi Z, Buonfrate D, Sequi M, et al. Diagnostic Accuracy of Five Serologic Tests
563 for *Strongyloides stercoralis* Infection. *PLoS Negl Trop Dis* 2014; 8: e2640.
- 564 26 Riera C, Vergés M, López-Chejade P, et al. Desarrollo y evaluación de una técnica
565 ELISA con antígeno crudo de *Trypanosoma cruzi* para el diagnóstico de la Enfermedad de
566 Chagas. *Enferm emerg* 2009;11(1):22-29.
- 567 27 Saz J, Dalmau-Bueno A, Meulbroek M, et al. Use of fourth-generation rapid
568 combined antigen and antibody diagnostic tests for the detection of acute HIV infection in a
569 community centre for men who have sex with men, between 2016 and 2019. *PLoS One* 2021
570 Jul 27;16(7):e0255065. DOI:10.1371/JOURNAL.PONE.0255065.
- 571 28 Mayer-Blackwell K, Johnson AM, Potchen N, et al. Multi-trial analysis of HIV-1
572 envelope gp41-reactive antibodies among global recipients of candidate HIV-1 vaccines.
573 *Front Immunol* 2022 Oct 12;13:983313.
- 574 29 Krolewiecki AJ, Ramanathan R, Fink V, et al. Improved diagnosis of *Strongyloides*
575 *stercoralis* using recombinant antigen-based serologies in a community-wide study in
576 northern Argentina. *Clinical and Vaccine Immunology* 2010; 17: 1624–30.
- 577 30 Fradejas I, Herrero-Martínez JM, Lizasoain M, Rodríguez De Las Parras E, Pérez-
578 Ayala A. Comparative study of two commercial tests for *Strongyloides stercoralis* serologic
579 diagnosis. *Trans R Soc Trop Med Hyg* 2018; 112: 561–7.
- 580 31 Tanigawa C, Fujii Y, Miura M, et al. Species-Specific Serological Detection for
581 Schistosomiasis by Serine Protease Inhibitor (SERPIN) in Multiplex Assay. *PLoS Negl Trop*
582 *Dis* 2015; 9: e0004021.
- 583 32 NICE: The National Institute for Health and Care excellence. Hepatitis B and C
584 testing: people at risk of infection. 2012. URL: <https://www.nice.org.uk/guidance/ph43>.
585 (Accessed June 8, 2023).
- 586 33 Marohnic CC, Birkenmeyer LG, Bogdan MF, et al. Engineering of the hepatitis C
587 virus helicase for enhanced seroreactivity. *J Virol Methods* 2019; 264: 11–7.
- 588 34 Interpretation of Hepatitis B Serologic Test Results | CDC.
589 <https://www.cdc.gov/hepatitis/hbv/interpretationOfHepBSerologicResults.htm> (accessed May
590 31, 2023).

- 591 35 Egui A, Carmen Thomas M, Fernández-Villegas A, et al. A Parasite Biomarker Set
592 for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic
593 *Trypanosoma cruzi* Infection. *Antimicrob Agents Chemother* 2019 Sep 23;63(10):e02436-18.
594 DOI:10.1128/AAC.02436-18/SUPPL_FILE/AAC.02436-18-S0001.PDF.
- 595 36 Ubillos I, Aguilar R, Sanz H, et al. Analysis of factors affecting the variability of a
596 quantitative suspension bead array assay measuring IgG to multiple *Plasmodium* antigens.
597 *PLoS One* 2018; 13: e0199278.
- 598 37 Viana IFT, Coêlho DF, Palma ML, et al. Detection of IgG3 antibodies specific to the
599 human immunodeficiency virus type 1 (HIV-1) p24 protein as marker for recently acquired
600 infection. *Epidemiol Infect* 2018; 146: 1293–300.
- 601 38 Brust S, Duttmann H, Gürtler L, Thortensson R, Simon F. Shortening of the
602 diagnostic window with a new combined HIV p24 antigen and anti-HIV-1/2/O screening test.
603 *J Virol Methods* 2000; 90: 153–65.
- 604 39 Gauna A, Losada S, Lorenzo M, et al. Use of Synthetic Peptides and Multiple Antigen
605 Blot Assay in the Immunodiagnosis of Hepatitis C Virus Infection. *Viral Immunol* 2018; 31:
606 568–74.
- 607 40 Gam AA, Neva FA, Krotoski WA. Comparative sensitivity and specificity of ELISA
608 and IHA for serodiagnosis of strongyloidiasis with larval antigens. *Am J Trop Med Hyg*
609 1987; 37: 157–61.
- 610 41 Kelly EA, Bulman CA, Gunderson EL, et al. Comparative Performance of Latest-
611 Generation and FDA-Cleared Serology Tests for the Diagnosis of Chagas Disease. *J Clin*
612 *Microbiol* 2021 May 19;59(6):e00158-21. DOI:10.1128/JCM.00158-21.
- 613 42 Arnold B, Scobie H, Priest J, Lammie P. Integrated serologic surveillance of
614 population immunity and disease transmission. *Emerg Infect Dis* 2018; 24: 1188–94.
- 615 43 Priest J, Jenks M, Moss D, et al. Integration of multiplex bead assays for parasitic
616 diseases into a national, population-based serosurvey of women 15-39 years of age in
617 Cambodia. *PLoS Negl Trop Dis* 2016 May 3;10(5):e000469.
- 618 44 Fujii Y, Kaneko S, Nzou S, et al. Serological surveillance development for tropical
619 infectious diseases using simultaneous microsphere-based multiplex assays and finite mixture
620 models. *PLoS Negl Trop Dis* 2014 Jul 31;8(7):e304.
- 621 45 McManus M, Karalius B, Patel K, Persaud D, Luzuriaga K. Quantitative HIV-1-
622 specific antibodies as predictors of peripheral blood cell-associated HIV-1 DNA
623 concentrations. *AIDS* 2020; 34: 1117–26.
- 624 46 Santano R, Rubio R, Grau-Pujol B, et al. Evaluation of antibody serology to
625 determine current helminth and *Plasmodium falciparum* infections in a co-endemic area in
626 Southern Mozambique. *PLoS Negl Trop Dis* 2022 Jun 21;16(6):e0010138.
- 627 47 Tanigawa C, Fujii Y, Miura M, et al. Species-Specific Serological Detection for
628 Schistosomiasis by Serine Protease Inhibitor (SERPIN) in Multiplex Assay. *PLoS Negl Trop*
629 *Dis* 2015 Aug 20;9(8):e000402.

630 48 Sillanpää M, Melén K, Porkka P, et al. Hepatitis C virus core, NS3, NS4B and NS5A
631 are the major immunogenic proteins in humoral immunity in chronic HCV infection. *Virology*
632 2009; 6: 1–12.

633 49 Lee JH, Kim HS. Current laboratory tests for diagnosis of hepatitis B virus infection.
634 *Int J Clin Pract* 2021; 75: e14812.

635 50 Caviglia GP, Olivero A, Ciancio A, et al. Analytical and clinical evaluation of a novel
636 assay for anti-HBc IgG measurement in serum of subjects with overt and occult HBV
637 infection. *Diagn Microbiol Infect Dis* 2020 Apr;96(4):114985.

638 51 Alonso-Padilla J, López MC, Esteva M, et al. Serological reactivity against T. cruzi-
639 derived antigens: Evaluation of their suitability for the assessment of response to treatment in
640 chronic Chagas disease. *Acta Trop* 2021 Sep;221:105990.

641

642

643

644

645

646

647

648

649 **TABLES**

650 Table 1. The 10 antigens tested used in the multi-infection Luminex assay

651

Antigen	Pathogen	Source	Coupling concentration	Reference
Recombinant HIV1 p24 protein	HIV	Abcam ab43037	30µg/mL	³⁷
Recombinant HIV1 gp41 protein	HIV	Abcam ab49068	250µg/mL	⁴⁵
NIE	Strongyloides	Expressed in <i>E. coli</i> by Sukwan Handali (CDC) from a plasmid clone donated by Thomas Nutman (NIH/NIAID), USA	10µg/mL	⁴⁶
Sm serpin	<i>Schistosoma mansoni</i>	Donated by Satoshi Kaneko (Nagasaki University, Japan)	30µg/mL	⁴⁷
Sh serpin	<i>Schistosoma haematobium</i>	Donated by Satoshi Kaneko (Nagasaki University, Japan)	50µg/mL	⁴⁷
Recombinant Hepatitis C Virus NS3 protein	HCV	Abcam ab49024	50µg/mL	⁴⁸
Recombinant Hepatitis C Virus Core Antigen	HCV	Abcam ab49017	50µg/mL	⁴⁸
Recombinant Hepatitis B Virus Core Antigen	HBV	Abcam ab49013	30µg/mL	^{49, 50}
Chagas PFR2	<i>Trypanosoma cruzi</i>	Recombinant protein produced by Carmen Thomas and Manuel C. Lopez, IPBLN-CSIC, Granada, Spain	50µg/mL	⁵¹
Chagas KMP11	<i>Trypanosoma cruzi</i>	Recombinant protein produced by Carmen Thomas and Manuel C. Lopez IPBLN-CSIC, Granada, Spain)	30µg/mL	⁵¹

HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus; Sm: *Schistosoma mansoni*; Sh: *Schistosoma haematobium*; NS3: non-structural protein 3; PFR2: paraflagellar rod protein 2; KMP11: kinetoplastid membrane protein-11

652

Table 2. Performance parameters of the 10 antigens tested in the multiplex assay on a reference panel of human samples

	Antigens	2 SD cutoff					3 SD cutoff					AUC
		Pos T / Pos GS	Sensitivity	Neg T / Neg GS	Specificity	Correctly classified	Pos T / Pos GS	Sensitivity	Neg T / Neg GS	Specificity	Correctly classified	
HIV	p24	35/40	87.5	31/32	96.9	91.7	32/40	80.0	32/32	100	88.9	0.93 (0.88-0.99)
	gp41	40/40	100	32/32	100	100	40/40	100	32/32	100	100	1.00 (1.00-1.00)
	Both	40/40	100	31/32	96.9	98.6	40/40	100	32/32	100	100	1.00 (1.00-1.00)
HBV	HBV core	39/40	97.5	32/32	100	98.6	38/40	95	32/32	100	97.2	0.99 (0.96-1.00)
HCV	HCV core	40/40	100	32/32	100	100	39/40	97.5	32/32	100	98.6	1.00 (1.00-1.00)
	HCV NS3	33/40	82.5	31/32	96.9	88.9	31/40	77.5	32/32	100	87.5	0.91 (0.85-0.97)
	Both	40/40	100	31/32	96.9	98.6	39/40	97.5	32/32	100	98.6	1.00 (1.00-1.00)
Chagas disease	PFR2	31/40	77.5	30/32	93.8	84.7	17/40	42.5	32/32	100	68.1	0.87 (0.80-0.94)
	KMP11	37/40	92.5	31/32	96.9	94.4	34/40	85.0	32/32	100	91.7	0.96 (0.92-1.00)
	Both	38/40	95.0	29/32	90.6	93.1	34/40	85.0	32/32	100	91.7	0.97 (0.93-1.00)
<i>Strongyloides</i>	NIE	37/40	92.5	29/32	90.6	91.7	37/40	92.5	32/32	100	95.8	0.96 (0.91-1.00)
<i>Schistosoma</i> spp	Sm - serpin	36/40	90.0	31/32	96.9	93.1	31/40	77.5	32/32	100	87.5	0.95 (0.90-1.00)
	Sh - serpin	36/40	90.0	31/32	96.9	93.1	29/40	72.5	31/32	96.9	83.3	0.92 (0.87-0.99)
	Both	39/40	97.5	30/32	93.8	95.8	36/40	90.0	31/32	96.9	93.1	0.97 (0.93-1.00)

Pos T: positive test; Pos GS: positive Gold Standard; Neg T: Negative test; Neg GS: Negative Gold standard; HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus; Sm: *Schistosoma mansoni*; Sh: *Schistosoma haematobium*; NS3: non-structural protein 3; PFR2: paraflagellar rod protein 2; KMP11: kinetoplastid membrane protein-11

Table 3. Performance parameters of the 10 antigens tested in the multiplex assay in a prospective cohort of 48 migrant individuals with risk of exposure to the tested infections.

	Antigens	2 SD cutoff					3 SD cutoff					AUC
		Pos T / Pos GS	Sensitivity	Neg T / Neg GS	Specificity	Correctly classified	Pos T / Pos GS	Sensitivity	Neg T / Neg GS	Specificity	Correctly classified	
HIV	p24	0/1	0	43/45	95.6	93.5	0/1	0	43/45	95.6	93.5	0.48 (. - 1.00)
	gp41	1/1	100	39/45	86.7	87.0	0/1	0	44/45	97.8	95.7	0.92 (. - 1.00)
HBV	HBV core	11/11	100	33/37	89.2	91.7	7/11	63.6	35/37	94.6	87.5	0.95 (0.90-1.00)
HCV	HCV core	-	-	46/48	95.8	-	-	-	47/48	97.9	-	-
	HCV NS3	-	-	45/48	93.8	-	-	-	45/48	93.8	-	-
Chagas disease	PFR2	14/14	100	16/16	100	100	12/14	85.7	16/16	100	93.3	1.00 (1.00-1.00)
	KMP11	14/14	100	16/16	100	100	14/14	100	16/16	100	100	1.00 (1.00-1.00)
	Both	14/14	100	16/16	100	100	14/14	100	16/16	100	100	1.00 (1.00-1.00)
<i>Strongyloides</i>	NIE	5/6	83.3	33/38	86.8	86.4	4/6	66.7	37/38	97.4	93.2	0.88 (0.70-1.00)
<i>Schistosoma</i> spp	Sm - serpin	-	-	20/22	90.0	-	-	-	21/22	95.4	-	-
	Sh - serpin	-	-	18/22	81.8	-	-	-	21/22	95.4	-	-
	Both	-	-	18/22	81.8	-	-	-	21/22	95.4	-	-

Pos T: Positive test; Pos GS: Positive Gold Standard; Neg T: Negative test; Neg GS: Negative Gold standard; HIV: Human Immunodeficiency Virus, HBV: Hepatitis B Virus, HCV: Hepatitis C Virus; Sm: *Schistosoma mansoni*; Sh: *Schistosoma haematobium*; NS3: non-structural protein 3; PFR2: paraflagellar rod protein 2; KMP11: kinetoplastid membrane protein-11

FIGURES

Figure 1. Dot plots showing the distribution of IgG levels measured against the 10 multiplexed antigens in the different panels of samples

1A. Panels of positive and negative control samples for each infection

1B. Panel of test samples from the migrants cohort

Legend:

The positive samples (1A) were selected based on seropositivity in the reference methods. In total, 40 positive samples were included for the respective infections (n=240).

Log₁₀MFI: IgG serological levels (log₁₀ mean fluorescence intensity); HBV: Hepatitis B Virus, HCV: Hepatitis C Virus; Sm: *Schistosoma mansoni*; Sh: *Schistosoma haematobium*

Figure 2. Receiver operating curves for the 10 antigens tested in the multiplex assay to detect the infections.





